Most dysplastic nevi never become melanoma. About 30% of dysplastic nevi associated with BRAF or NRAS mutations are at risk of cancerous transformation. The lifetime risk of melanoma in the United States is less than 1% but it increases to more than 10% in people with atypical nevi.